ArticleScientific reports2019
A novel anti Candida albicans drug screening system based on high-throughput microfluidic chips.
Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Exploring fungal survival mechanisms: toward next-generation antifungal therapies against Candida spp.Archives of microbiology · 2025Review
- Microfluidics as a promising technology for personalized medicine.BioImpacts : BI · 2025Review
- In Situ Aqueous Spice Extract-Based Antifungal Lock Strategy for Salvage of Foley's Catheter Biofouled withGels (Basel, Switzerland) · 2025Article
- Peptide-Mediated Nanocarriers for Targeted Drug Delivery: Developments and Strategies.Pharmaceutics · 2024Review
- Fungi-on-a-Chip: microfluidic platforms for single-cell studies on fungi.FEMS microbiology reviews · 2022Review
- Application and prospects of high-throughput screening forWorld journal of stem cells · 2022Review
- High-throughput precise particle transport at single-particle resolution in a three-dimensional magnetic field for highly sensitive bio-detection.Scientific reports · 2022Article
- Refining Host-Pathogen Interactions: Organ-on-Chip Side of the Coin.Pathogens (Basel, Switzerland) · 2021Review
- Combination Therapy to Treat Fungal Biofilm-Based Infections.International journal of molecular sciences · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Due to the antibacterial resistance crisis, developing new antibacterials is of particular interest. In this study, we combined the antifungal drug amphotericin B with 50,520 different small molecule compounds obtained from the Chinese National Compound Library in an attempt to improve its efficacy against Candida albicans persister cells. To systematically study the antifungal effect of each compound, we utilized custom-designed high-throughput microfluidic chips. Our microfluidic chips contained microchannels ranging from 3 µm to 5 µm in width to allow Candida albicans cells to line up one-by-one to facilitate fluorescence-microscope viewing. After screening, we were left with 10 small molecule compounds that improved the antifungal effects of amphotericin B more than 30% against Candida albicans persister cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.